Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Saving the lung from ozone pollutant: a new role of hyaluronan in alveolar regeneration.

American journal of respiratory cell and molecular biology·2026

Same author

Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor cell renewal in idiopathic pulmonary fibrosis.

The Journal of clinical investigation·2026

Same author

Syndecan-1 Promotes Alveolar Type 2 Epithelial Cell Senescence during Lung Fibrosis.

bioRxiv : the preprint server for biology·2026

Same author

Cellular heterogeneity of HTII-280-labeled epithelial cells in healthy and fibrotic human lungs.

American journal of respiratory and critical care medicine·2026

Same author

Phosphatidylcholine Metabolism Controls Alveolar Progenitor Renewal and Pulmonary Fibrosis.

bioRxiv : the preprint server for biology·2025

Same author

From fibroblast foci to dense scars: PAK2-activated fibroblasts drive fibrosis progression in idiopathic pulmonary fibrosis.

The European respiratory journal·2025

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Idiopathic pulmonary fibrosis.

Eric B Meltzer¹, Paul W Noble

¹Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina 27710, USA. eric.meltzer@duke.edu

Orphanet Journal of Rare Diseases

|March 28, 2008

Summary

Idiopathic pulmonary fibrosis (IPF) is a progressive lung scarring disease affecting millions globally. Current medical therapies are ineffective, but new treatments and lung transplantation offer hope for improved outcomes.

Area of Science:

Pulmonology
Pathology
Radiology

Background:

Idiopathic pulmonary fibrosis (IPF) is a non-neoplastic lung disease characterized by progressive scarring.
It affects approximately 5 million people worldwide, with a higher prevalence in men, typically presenting around age 66.
Symptoms include breathlessness, dry cough, inspiratory crackles, and clubbing, with cor pulmonale in end-stage disease.

Purpose of the Study:

To summarize the current understanding of idiopathic pulmonary fibrosis (IPF).
To outline diagnostic criteria and differential diagnoses for IPF.
To discuss current treatment limitations and future therapeutic directions.

Main Methods:

Diagnosis relies on correlating clinical presentation, high-resolution computed tomography (HRCT) findings, and lung biopsy.

Related Experiment Videos

Last Updated: Jul 6, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

HRCT shows peripheral, subpleural lower lobe reticular opacities with honeycomb changes, consistent with usual interstitial pneumonia (UIP).

Differential diagnosis includes other interstitial lung diseases, connective tissue diseases, and environmental exposures.

Main Results:

IPF is characterized by usual interstitial pneumonia (UIP) pattern, featuring alternating normal lung and dense fibrotic patches.
The disease is typically progressive, leading to significant disability and a median survival of 2-5 years post-diagnosis.
Current medical therapies are largely ineffective for IPF.

Conclusions:

Idiopathic pulmonary fibrosis (IPF) is a devastating illness with limited treatment options.
New molecular targets are under investigation, and clinical trials are exploring novel medications.
Pulmonary transplantation remains a viable option, with expectations of significant progress in understanding and treating IPF in the coming decade.